ALT

7.15

6.04% -0.46

Handel nachbörslich: 7.13 -0.02 -0.28%

Altimmune Inc (ALT)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit Dividendenhistorie

Schlusskurs vom Vortag:

$7.61

Offen:

$7.55

24-Stunden-Volumen:

4.44M

Relative Volume:

1.67

Marktkapitalisierung:

$508.16M

Einnahmen:

$409.00K

Nettoeinkommen (Verlust:

$-101.35M

KGV:

-4.3865

EPS:

-1.63

Netto-Cashflow:

$-71.49M

1W Leistung:

-2.72%

1M Leistung:

+3.92%

6M Leistung:

-10.74%

1J Leistung:

+193.03%

1-Tages-Spanne:

$6.945

$7.59

1-Wochen-Bereich:

$6.945

$11.16

52-Wochen-Spanne:

$2.41

$14.84

Altimmune Inc Stock (ALT) Company Profile

Firmenname

Altimmune Inc

Sektor

Healthcare (1196)

Branche

Biotechnology (683)

Telefon

(240) 654-1450

Adresse

910 CLOPPER ROAD, GAITHERSBURG, MD

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-11-05

Neueste SEC-Einreichungen

ALT's Discussions on Twitter

Vergleichen Sie ALT mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ALT	7.15	508.16M	409.00K	-101.35M	-71.49M	-1.63
VRTX	467.01	119.87B	10.63B	-479.80M	-1.35B	13.33
REGN	762.00	83.27B	13.85B	4.65B	3.32B	35.06
ARGX	567.90	33.96B	1.86B	-40.29M	-1.28B	-4.16
ALNY	232.27	30.18B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.87	24.42B	3.30B	-501.07M	1.03B	11.54

Altimmune Inc Stock (ALT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-04-29	Herabstufung	Guggenheim	Buy → Neutral
2024-01-24	Eingeleitet	Goldman	Neutral
2023-03-22	Herabstufung	Goldman	Buy → Neutral
2022-12-01	Eingeleitet	Goldman	Buy
2021-12-29	Fortgesetzt	Jefferies	Buy
2021-06-02	Eingeleitet	H.C. Wainwright	Buy
2021-02-11	Eingeleitet	Guggenheim	Buy
2020-12-14	Eingeleitet	Jefferies	Buy
2020-11-12	Bestätigt	B. Riley Securities	Buy
2020-09-25	Eingeleitet	B. Riley FBR	Buy
2020-08-14	Eingeleitet	Evercore ISI	Outperform
2020-07-31	Eingeleitet	Piper Sandler	Overweight
2020-07-28	Eingeleitet	JMP Securities	Mkt Outperform
2020-02-24	Fortgesetzt	ROTH Capital	Buy
2019-07-19	Eingeleitet	ROTH Capital	Buy
2017-10-09	Eingeleitet	Piper Jaffray	Overweight

Alle ansehen

Altimmune Inc Aktie (ALT) Neueste Nachrichten

02:52 AM

HC Wainwright Decreases Earnings Estimates for Altimmune - MarketBeat

02:52 AM

01:54 AM

Altimmune, Inc. (NASDAQ:ALT) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

01:54 AM

Nov 16, 2024

(ALT) Trading Report - Stock Traders Daily

Nov 16, 2024

Nov 15, 2024

Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024 - The Manila Times

Nov 15, 2024

Altimmune, Inc. Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease at The Liver Meeting 2024 - Marketscreener.com

Nov 15, 2024

What is B. Riley's Forecast for Altimmune FY2024 Earnings? - MarketBeat

Nov 15, 2024

Nov 14, 2024

AMERIPRISE FINANCIAL INC's Strategic Acquisition in Altimmune Inc - GuruFocus.com

Nov 14, 2024

Altimmune: Pemvidutide As MASH Drug Could Provide Competitive Edge (NASDAQ:ALT) - Seeking Alpha

Nov 13, 2024

Altimmune Unusual Options Activity For November 13 - Benzinga

Nov 13, 2024

Altimmune’s Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health (ALT) - Seeking Alpha

Nov 13, 2024

Altimmune provided key pipeline updates with Q3 report, says B. Riley - TipRanks

Nov 13, 2024

Altimmune, Inc. (NASDAQ:ALT) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 13, 2024

UBS Initiates Coverage of Altimmune (ALT) with Buy Recommendation - Nasdaq

Nov 13, 2024

GSA Capital Partners LLP Sells 148,530 Shares of Altimmune, Inc. (NASDAQ:ALT) - MarketBeat

Nov 13, 2024

Earnings call: Altimmune reports progress on pemvidutide trials, financials - Investing.com India

Nov 13, 2024

Earnings call: Altimmune reports progress on pemvidutide trials, financials By Investing.com - Investing.com Canada

Nov 13, 2024